Navigation Links
Isis Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
Date:1/6/2011

CARLSBAD, Calif., Jan. 6, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at J.P. Morgan's 29th Annual Healthcare Conference on Thursday, January 13, 2011 at 8:00 a.m. PST at the Westin St. Francis Hotel in San Francisco, CA.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 24 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis has designed and executed a patent strategy that has provided the Company with strong and extensive protection for Isis' drugs as well as all aspects of antisense drug discovery, development and manufacturing.  Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Former FDA Commissioner Joins Bexion Pharmaceuticals Board
2. Generex and RXi Pharmaceuticals Announce Positive Research Data Using RNAi Technology in the Development of Therapeutic Vaccines for Cancer
3. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
4. Cumberland Pharmaceuticals Announces Joey Jacobs Has Joined Its Board of Directors
5. ISTA Pharmaceuticals Achieves 2010 Revenue and Earnings Guidance; Provides 2011 Financial Guidance and Updates Key Plans
6. Omthera Pharmaceuticals, Inc. to Present at the 29th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Obtains Additional Fidaxomicin Patent
8. Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development
9. Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference in San Francisco on January 12
10. MAP Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
11. Lexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , April 27, 2016 Transparency ... "Skincare Devices Market - Global Industry Analysis, Size, Share, ... the report, the global skincare devices market was valued ... to expand at a CAGR of 10.1% from 2015 ... Browse the full Skincare Devices Market (Treatment Device ...
(Date:4/27/2016)... Kan. , April 27, 2016  Bayer ... , a senior from the University of Florida ... of the Bayer Excellence in Communication Award (BECA). ... schools, which were awarded a total of $70,000 ... the last four years, Bayer has provided a ...
(Date:4/27/2016)... April 27, 2016 Oasmia ... developer of a new generation of drugs within ... survival results for Paclical/Apealea in the Phase III ... with epithelial ovarian cancer. These preliminary results showed ... combination with carboplatin versus Taxol in combination with ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... Horizon Blue Cross Blue Shield ... hospitals to make transformative changes in how health care is delivered and financed ... in discussing breakthroughs in cellular medicine to treat disease. After accepting an invitation ...
(Date:4/28/2016)... ... April 28, 2016 , ... One way to ignore solid evidence ... unfortunately true. But we toss the baby out with the bathwater when we ignore ... for identifying higher-quality studies and otherwise making better use of education policy research. , ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... leader in Aesthetic Surgery Education and Anzu®, developers of the AnzuMedical™ Knowledge ... Nationwide Plastic Surgery Collaborative Residency Network. The platform is scheduled to launch in ...
(Date:4/28/2016)... ... April 28, 2016 , ... A first-time look at workers’ compensation claims in ... Workers Compensation Research Institute (WCRI) announced, and that costs per claim were ... Kentucky, 16th Edition , found that indemnity costs per claim and benefit delivery expenses ...
(Date:4/28/2016)... ... April 28, 2016 , ... Metabolic Nutrition today announced ... week’s 2016 Europa Games Get Fit and Sports Expo in Orlando, Florida. ... Orlando Expo coming up April 29-30, was selected as the perfect event to introduce ...
Breaking Medicine News(10 mins):